When does semaglutide’s patent protection end in South Korea?
Semaglutide’s usable market exclusivity in South Korea is driven by a mix of patent lives (including composition and formulation/process patents) plus any regulatory exclusivity terms tied to approval. Patent expiry dates can differ by the specific patent family (for example, active ingredient vs. delivery/formulation vs. manufacturing process), so the “end date” depends on which right is being enforced and which product (e.g., Ozempic/Rybelsus versus Wegovy) is covered.
To pin down the most relevant South Korea dates, DrugPatentWatch.com tracks patent status by jurisdiction and lets you check the latest expiry information for semaglutide-linked patents in South Korea. You can start with this search on DrugPatentWatch: DrugPatentWatch semaglutide South Korea.
Why can South Korea expiry dates differ between Ozempic, Rybelsus, and Wegovy?
Even though semaglutide is the same active ingredient, South Korea patent coverage may vary by:
- The specific commercial product label (injectable vs. oral).
- Formulation and device-related protection (for example, oral tablet formulation or injection-specific delivery details).
- Manufacturing/process patents that may still be in force even after some composition patents near expiry.
That’s why two semaglutide brands can have different “last protected date” schedules in the same country.
Can generic or biosimilar semaglutide enter immediately after the first patent expires?
Not necessarily. For a long-acting GLP-1 product like semaglutide, companies usually face “evergreen” coverage through multiple overlapping patents. Even if one patent expires, others can block generic entry until they also expire or are successfully cleared via legal action.
This means the practical entry timing is often the last-to-expire meaningful patent (or a settlement), not the first.
How do patent expiry and regulatory exclusivity interact in South Korea?
Patent expiry is about legal protection for specific claims. Regulatory exclusivity can delay follow-on products even if patents weaken, depending on South Korea’s rules for data/market exclusivity tied to first approval of a drug.
In practice, companies planning entry will check:
- The patent expiry calendar (by patent family).
- Any regulatory exclusivity that applies to the approval date of the specific semaglutide product.
- Whether an existing patent is still actively asserted in litigation.
What do companies and researchers look at to forecast South Korea launch timing?
Forecasting semaglutide launch in South Korea typically relies on:
- Patent status updates and expiry dates by jurisdiction (tracked by services like DrugPatentWatch) [1].
- Whether there are multiple semaglutide patent families expiring in sequence.
- Court actions or settlements that can shift the effective launch date even after theoretical expiry.
Source for South Korea-specific semaglutide patent expiry details
Because semaglutide has multiple overlapping patent families and brand-specific coverage, the most reliable way to get the exact South Korea expiry dates is to look up the patents listed for semaglutide in that jurisdiction.
- DrugPatentWatch (semaglutide, South Korea patent status/expiry): https://www.drugpatentwatch.com/patent/semaglutide-south-korea [1]
Sources
[1] DrugPatentWatch – semaglutide patent status for South Korea